-
Development & Use of an Interactive Online Dashboard for CTN-0135
CTN-0135, Buprenorphine Treatment Engagement and Induction Problems Among Individuals Using Fentanyl, examined whether fentanyl use and challenges starting buprenorphine/naloxone treatment vary across different regions in the U.S. The study also surveyed clinicians to better understand the challenges they face when starting buprenorphine treatment for patients using fentanyl and how they are adapting standard clinical protocols to better engage patients in care. Recognizing that scientific journals have low overall reach, particularly for non-scientific audiences, the study team created an interactive online data dashboard to make the data more accessible. After developing a draft, they asked 364 of the original survey participants (those who had agreed to future contact) to evaluate the dashboard’s usability. Feedback was encouraging! Overall, 84.4% of respondents were at least somewhat satisfied with the dashboard, 91.7% said the results were relevant to clinical practice, and 77.7% said they would be likely to use a data dashboard to learn about study results. Users praised the dashboard’s simplicity and ease of use. Suggestions for improvements included changes to the color scheme and font sizes and reducing scrolling. Overall, the evaluation suggests that interactive online dashboards are a practical way to share research findings with clinicians. Future work should consider ways to involve users in the development process and consider differences in data visualization approaches and computer skills. For more details, check out the study team’s presentation at CPDD 2026: CTN-0135: Development & use of an interactive, web-based platform to share scientific findings. Explore the CTN-0135 Trends in Drug Use…
-
News from the Health Systems Node
Join the CTN Health Systems Node for two upcoming virtual seminars. On Thursday, August 6, 2026, Caitlin Ryus, MD, MPH, Assistant Professor in the Department of Emergency Medicine at Yale School of Medicine, will discuss a Connecticut-based study that links administrative data from homelessness services and electronic health records to examine the relationship between rapid rehousing and substance-related emergency department visits. On Thursday, September 3, 2026, Tessa Matson, PhD, MPH, Collaborative Scientist at Kaiser Permanente Washington Health Research Institute, will present findings from a CTN implementation trial on factors that distinguished clinics that successfully increased opioid use disorder treatment from those that did not. Both seminars will be held at 10:00 AM PT / 1:00 PM ET via Microsoft Teams. Meeting ID: 250 658 877 216 6 | Passcode: B8jq2m9A.
-
Research in Addiction Medicine (RAMS) Program: Recruitment for 15th Cohort Open!
-
New in the Library (June – July 2026)
Here are the latest items added to the CTN Dissemination Library for June – July 2026 (this post will be updated as new items come in): Collaborative care intervention for risky opioid use among primary care patients: The STOP randomized clinical trial. McNeely J, et al. Addiction 2026 (in press). (Primary outcomes for CTN-0101) State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset. Bórquez I, et al. Addiction 2025;120(6):1207-1222. (CTN-0112) Actions needed for pharmacy-dispensed methadone for opioid use disorder in the United States. Weinstein ZM, et al. Journal of General Internal Medicine 2026;41(4):1138-1141. (CTN-0131) Health outcomes associated with patterns of substance use disorders among patients with type 2 diabetes and hypertension: Electronic health record findings. Kahn MTF, et al. Primary Care Diabetes 2023;17(1):43-47. Relationship between depression on cocaine craving over time amongst patients in a trial evaluating the use of buprenorphine on cocaine use. Rodin NM, et al. Drug and Alcohol Dependence Reports 2026;20:100460. (CTN-0148) Methodological innovations to advance substance use disorder research: Proceedings of a NIDA workshop on target trial emulation and translational testing of digital health tools [commentary]. Hall LC, et al. Journal of Substance Use and Addiction Treatment 2026 (in press). CTN-0135: Development & use of an interactive, web-based platform to share scientific findings. Winstanley EL, et al. Presented at the College on Problems of Drug Dependence (CPDD) annual meeting, June 13-17, 2026. Posted on July 9, 2026; Updated July 16
-
News from the Southern Consortium Node: New CTN SIG: Substance Use Research in Non-Traditional Settings
Join the new NIDA Clinical Trials Network Special Interest Group on Substance Use Research in Non-Traditional Settings! Led by the Southern Consortium Node, this SIG will bring together researchers and community partners interested in advancing substance use prevention, treatment, recovery, harm reduction, and implementation research in community-based settings outside of traditional specialty treatment programs. Topics include research in: Meetings will feature research presentations, discussion of emerging evidence and funding opportunities, networking, and collaboration on future research initiatives. First Meeting: Wednesday, August 19, at 2:00 p.m. ET Meeting Link (Microsoft Teams): CTN SIG Substance Use Research in Non-traditional Settings We welcome investigators, clinicians, community partners, and others interested in expanding access to evidence-based substance use interventions in non-traditional settings. To learn more, feel free to contact the SIG leads, Dr. Christina Andrews (candrews@mailbox.sc.edu) and Dr. Tina Lopez (lopezcm@musc.edu). Posted on July 13, 2026
-
THIS WEDNESDAY (July 15): National Contingency Management Community of Practice
The National Contingency Management (CM) Community of Practice (CoP), led by Michigan Medicine (University of Michigan), is intended to serve as a collaborative learning forum, bringing together researchers, treatment providers, implementers, TTA leaders, state agencies, and other partners in CM interested in expanding access to evidence-based CM. The goal is to create a practical, engaging, and implementation-focused space to share best practices, discuss challenges and solutions, and support broader adoption and sustainability of evidence-based CM across the U.S. Join the CM CoP monthly meetings to ask questions, share what is working, and learn from CM experts across the country! The first meeting of the National CM CoP is THIS WEDNESDAY, July 15, 2026, from 1-2pm ET. Find out more and register here!
-
News from the Pacific Northwest Node: ADAI Symposium on Cannabinoid Hyperemesis Syndrome (Sept. 18, 2026)
The CTN Pacific Northwest Node is located at the Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington. Every two years, ADAI hosts a symposium related to cannabis. The PNW Node would like to invite you to this year’s event and also encourage anyone familiar with CHS to consider submitting an abstract for a digital poster! The Dose Makes the Poison: Cannabinoid Hyperemesis Syndrome Goes Mainstream September 18, 2026 | 9:00am – 4:00pm PT Attend virtually or in person in Seattle, WA CME accreditation pending for providers; Certificate of attendance available for both in-person and virtual attendees Cannabinoid Hyperemesis Syndrome (CHS) is becoming increasingly visible in clinical settings, but many providers are navigating diagnosis, treatment, and patient communication without clear guidance. In a recent survey of Washington State healthcare providers, 70% reported treating patients experiencing severe abdominal pain, persistent nausea, retching, and relentless vomiting associated with heavy cannabis use. Patients may not recognize cannabis as the cause of their symptoms, or may be skeptical that CHS exists at all, making effective care even more challenging.
-
CTN T&I SIG Webinar: SUD Treatment Research in the CTN: Portfolio Analysis of Approved Studies, 2000-2024 (July 21, 9am PT)
Join the CTN Translation & Implementation SIG for their next meeting, July 21, 2026, 9-10am PT. Drs. Sabeeh Baig, Jeremiah Bertz, and Landhing Moran will describe the methods and findings from their comprehensive portfolio analysis of all studies within the CTN approved from 2000 through 2024. Their presentation will highlight scientific areas in the CTN portfolio, portfolio growth trends, and research impact through this period. The presentation will conclude with a discussion of the CTN’s achievements and the strengths of its trial infrastructure. Read more about the speakers. Contact Elena Rosenberg-Carlson at rosenbee@stanford.edu for the meeting link or to join the CTN T&I email list.
